Abstract 165P
Background
Sorafenib has been the standard-of-care in advanced hepatocellular carcinoma (HCC). Prognostic factors such as BCLC stage and macroscopic vascular invasion (MVI), together with predictive factors of response such as neutrophil-lymphocyte ratio (NLR), cirrhosis etiology and extrahepatic spread (EHS) were found to be associated to survival outcomes. Nevertheless, these factors need to be fully validated. We intend to explore and identify prognostic factors for overall survival (OS) in a European population sample treated with sorafenib.
Methods
Multicentre retrospective evaluation of patients’ (pts) charts of HCC pts with ECOG performance status (PS) ≤2 treated with sorafenib between 2008 and 2019 in two Portuguese centres. Alfa- fetoprotein (AFP) < 200 ng/mL, EHS, Model for End-Stage Liver Disease-Na (MELD-Na) < 17, cutaneous toxicity, NLR < 2.3, MVI and previous locoregional treatment (LRT) were considered for stratification. Each factor was analyzed by Kaplan-Meier method for OS estimation and a multivariate Cox regression was performed.
Results
Eighty-six pts were analyzed, 15% female and with a median age (med) of 65.5 years [36-83]. Considering underlying cause, 45% pts had alcohol-related liver disease, 23% hepatitis C virus, 14% hepatitis B virus and 5% non-alcoholic steatosis hepatitis. Median OS was 8.5 months (m). Kaplan-Meier analysis of OS proved to be statistical significant in the following factors: AFP < 200 ng/mL med OS 12.5 m and ≥ 200 ng/mL 5.4 m (p < 0.0001); MELD-Na < 17 med OS 10.4 m and ≥ 17 4.8 m (p=0.015); absence of EHS med OS 10.0 m and presence of EHS med OS 7.3 m (p=0.028); previous LRT med OS 11.2 m and no LRT med OS 6.6 m (p=0.005). Multivariate Cox analysis identified extra-hepatic involvement (HR 1.002, p=0.041) and no previous LRT (HR 1.871, p=0.009) as risk factors.
Conclusions
HCC pts represent a heterogeneous population with many factors that potentially affect prognosis, such as geographic etiology difference in hepatic cirrhosis. In our sample, analysis of single-variable subgroups estimated greater OS in pts with AFP < 200 ng/mL, MELD-Na < 17, absence of EHS and previous LRT. The multivariate regression showed EHS and no previous LRT are independent factors for worse prognosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
276P - Sarcopenia to predict overall survival in head and neck cancer patients receiving chemotherapy: A systematic review and meta-analysis
Presenter: Felix Kwenandar
Session: e-Poster Display Session
277P - Tegafur/uracil, platinum and cetuximab (UPEx) as first line treatment in frail patients with recurrent or metastatic head and neck squamous cell carcinoma
Presenter: Meng-che Hsieh
Session: e-Poster Display Session
278P - Serial assessment of parotid volume changes during radical chemoradiation of locally advanced head and neck cancer: Its implications in practice of adaptive radiotherapy
Presenter: Aathira T S
Session: e-Poster Display Session
279P - Clinico pathological characteristics and survival outcome in oral cavity cancer with masticator space involvement (T4b): A retrospective single institutional experience
Presenter: Abdulla Kunnummal Palathinkara
Session: e-Poster Display Session
280P - Safety and efficacy of concurrent chemoradiotherapy for head and neck cancers in younger versus older patients: Post hoc analysis of a randomized control trial
Presenter: Vanita Noronha
Session: e-Poster Display Session
281P - Prevalence of premalignant lesions and oral cancer among tobacco-using tea plantation workers of Nilgiri Hills, Tamilnadu, India
Presenter: Delfin Lovelina Francis
Session: e-Poster Display Session
282P - Filipino head and neck cancer patients and their quality of life
Presenter: Frederic Ivan Ting
Session: e-Poster Display Session
283P - Descriptive epidemiology of head and neck cancer in Niger: First results from the National Cancer Registry
Presenter: Salamatou Mamoudou Garba
Session: e-Poster Display Session
284P - Outcomes of metronomic adjuvant chemotherapy with tegafur-uracil in locally advanced head and neck squamous cell carcinoma
Presenter: Tsung-jang Yeh
Session: e-Poster Display Session
285P - Comparison of induction chemotherapy plus concurrent chemoradiotherapy and concurrent chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma: A meta-analysis
Presenter: Xu Guoqiang
Session: e-Poster Display Session